Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education; Shaanxi Provincial Key Laboratory of Biotechnology; College of Life Sciences, Northwest University, Xi'an 710069, PR China.
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education; Shaanxi Provincial Key Laboratory of Biotechnology; College of Life Sciences, Northwest University, Xi'an 710069, PR China.
J Pharm Biomed Anal. 2023 Mar 20;226:115253. doi: 10.1016/j.jpba.2023.115253. Epub 2023 Jan 14.
Rhizoma Drynariae (RD) was used clinically to treat osteoporosis in China due to stimulating bone formation and inhibiting bone resorption, however, the bioactive constituents with the dual effect on bone are still unknown exactly. Disease-causing mutations in calcium sensing receptor (CaSR) can alter parathyroid hormone secretion and affect Ca release from bone and Ca reabsorption from kidney, which gives an indication that CaSR is a potential target for developing therapeutics to manage osteoporosis. Herein, a chromatographic approach was established, by immobilizing the mutant CaSR onto the surface of silica gels as stationary phase in a one-step procedure and then adding the different amino acids into mobile phase as competitors, for exploring the binding features of the known agonists and further screening ligands from RD. The mutant CaSR-coated column was prepared rapidly without the complicated purification and separation of the receptor, which had the large capacity of 13.1 mg CaSR /g silica gels and kept a good stability and specificity for at least 35 days. The CaSR mutation can weaken the binding affinities for three agonists, and the largest decreases occurred on the mutational site Thr151Met for neomycin, on the two sites of Asn118Lys and Glu191Lys for gentamicin-C, and on the site Phe612Ser for kanamycin, which gained new insights into their structure-function relationship. The potential bioactive compounds from RD were screened using the mutant CaSR-coated column and were recognized as coumaric acid 4-O-β-D-glucopyranoside, caffeic acid, and naringin using UPLC-MS. Among them, naringin targeting CaSR gives a possible explanation that RD could manage osteoporosis. These results indicated that, such a rapid and simple method, utilizing disease-associated mutation in CaSR to alter the binding affinity for agonists, can be applied in capturing the potential bioactive compounds efficiently from complex matrices like herb medicines.
骨碎补(RD)在中国临床上用于治疗骨质疏松症,因为它可以刺激骨形成和抑制骨吸收,然而,确切地说,具有双重骨作用的生物活性成分仍不清楚。钙敏感受体(CaSR)的致病突变可以改变甲状旁腺激素的分泌,并影响骨钙释放和肾脏钙重吸收,这表明 CaSR 是开发治疗骨质疏松症药物的潜在靶点。在此,通过将突变的 CaSR 固定在硅胶表面作为固定相,在一步法中进行,然后在流动相中加入不同的氨基酸作为竞争物,建立了一种色谱方法,用于探索已知激动剂的结合特征,并进一步从 RD 中筛选配体。突变 CaSR 涂覆柱的制备快速,无需受体的复杂纯化和分离,该柱具有 13.1 mg CaSR/g 硅胶的大容量,至少 35 天保持良好的稳定性和特异性。CaSR 突变可以削弱三种激动剂的结合亲和力,突变 Thr151Met 位点对新霉素的亲和力降低最大,突变 Asn118Lys 和 Glu191Lys 位点对庆大霉素-C 的亲和力降低最大,突变 Phe612Ser 位点对卡那霉素的亲和力降低最大,这为它们的结构-功能关系提供了新的见解。使用突变 CaSR 涂覆柱筛选 RD 中的潜在生物活性化合物,并使用 UPLC-MS 鉴定为香豆素 4-O-β-D-吡喃葡萄糖苷、咖啡酸和柚皮苷。其中,柚皮苷靶向 CaSR 可能解释了 RD 可用于治疗骨质疏松症。这些结果表明,利用 CaSR 中的疾病相关突变改变激动剂的结合亲和力的这种快速简单的方法,可以有效地从草药等复杂基质中捕获潜在的生物活性化合物。